Solid tumor Clinical Trials in New York, NY

As of August 2026, 129 paid clinical trials are recruiting for Solid tumor in New York, New York. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: August 27, 2026.

Related specialties in New York

Oncology· 1,382

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

130 clinical trials for Solid tumor

·Clear filters·

Email me when a new solid tumor trial opens in New York, NY.

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

for Locally Advanced Solid Tumor

Sites in New York +19 more locations

Sponsor: Nuvalent Inc.

Sex: All·Age: 12+

Code: NCT05384626·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

for Cancer

Sites in New York +11 more locations

Sponsor: Alterome Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06835569·Phase 1·Recruiting·Listed Feb 2025

Apply to this trial

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

for Refractory Cancer

Drug: Nivolumab

Sites in New York +12 more locations

Sponsor: Immatics US, Inc.

Sex: All·Age: 18+

Code: NCT03686124·Phase 1, Phase 2·Recruiting·Listed Sep 2018

Apply to this trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

for Solid Tumor

Sites in New York +4 more locations

Sponsor: Eisai Inc.

Sex: All·Age: 18+

Code: NCT04300556·Phase 1, Phase 2·Recruiting·Listed Mar 2020

Apply to this trial

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

for Pancreatic Ductal Adenocarcinoma

Sites in New York +12 more locations

Sponsor: Verastem, Inc.

Sex: All·Age: 18+

Code: NCT07020221·Phase 1, Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

for Advanced Cancer

Sites in New York +14 more locations

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT05557045·Phase 1·Recruiting·Listed Sep 2022

Apply to this trial

QTX3034 in Patients With KRAS G12D Mutation

for Solid Tumors

Sites in New York, The Bronx +12 more locations

Sponsor: Quanta Therapeutics

Sex: All·Age: 18+

Code: NCT06227377·Phase 1·Recruiting·Listed Jan 2024

Apply to this trial

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

for Oncology

Sites in New York, Buffalo +11 more locations

Sponsor: Nested Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06326411·Phase 1·Recruiting·Listed Mar 2024

Apply to this trial

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

for Solid Tumors

Sites in New York +14 more locations

Sponsor: DualityBio Inc.

Sex: All·Age: 18+

Code: NCT06953089·Phase 2·Recruiting·Listed May 2025

Apply to this trial

A Study of YL201 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

Sites in New York +18 more locations

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Sex: All·Age: 18+

Code: NCT05434234·Phase 1, Phase 2·Recruiting·Listed Jun 2022

Apply to this trial

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

for Non Small Cell Lung Cancer

Sites in New York +14 more locations

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06810544·Phase 1, Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

for Locally Advanced Solid Tumor

Sites in New York +16 more locations

Sponsor: Nuvalent Inc.

Sex: All·Age: 18+

Code: NCT06521554·Phase 1·Recruiting·Listed Jul 2024

Apply to this trial

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

for Advanced Solid Tumor

Sites in New York +20 more locations

Sponsor: Clasp Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06778863·Phase 1·Recruiting·Listed Jan 2025

Apply to this trial

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

for Solid Tumor

Drug: Givastomig

Sites in New York +5 more locations

Sponsor: I-Mab Biopharma US Limited

Sex: All·Age: 18+

Code: NCT04900818·Phase 1·Recruiting·Listed May 2021

Apply to this trial

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

for Advanced Solid Tumor

Sites in New York +12 more locations

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT05932862·Phase 1·Recruiting·Listed Jul 2023

Apply to this trial

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

for Ovarian Cancer

Sites in New York +13 more locations

Sponsor: OnCusp Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06234423·Phase 1·Recruiting·Listed Jan 2024

Apply to this trial

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

Sites in New York +12 more locations

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Sex: All·Age: 18+

Code: NCT06859762·Phase 1·Recruiting·Listed Mar 2025

Apply to this trial

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for PIK3CA Mutation

Sites in New York +22 more locations

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05216432·Phase 1·Recruiting·Listed Jan 2022

Apply to this trial

Study of SGR-3515 In Participants With Advanced Solid Tumors.

for Advanced Solid Tumor

Sites in New York +12 more locations

Sponsor: Schrödinger, Inc.

Sex: All·Age: 18+

Code: NCT06463340·Phase 1·Recruiting·Listed Jun 2024

Apply to this trial

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

for Locally Advanced Solid Tumor

Sites in New York +18 more locations

Sponsor: Nuvalent Inc.

Sex: All·Age: 12+

Code: NCT05118789·Phase 1, Phase 2·Recruiting·Listed Nov 2021

Apply to this trial

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

for Solid Tumors

Sites in New York +16 more locations

Sponsor: ORIC Pharmaceuticals

Sex: All·Age: 18+

Code: NCT05315700·Phase 1, Phase 2·Recruiting·Listed Apr 2022

Apply to this trial

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

for Solid Tumor, Adult

Sites in New York +12 more locations

Sponsor: GV20 Therapeutics

Sex: All·Age: 18+

Code: NCT05669430·Phase 1, Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

Study of AVZO-021 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

Sites in New York, Mineola +9 more locations

Sponsor: Avenzo Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05867251·Phase 1, Phase 2·Recruiting·Listed May 2023

Apply to this trial

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

for Solid Tumor, Adult

Sites in New York +9 more locations

Sponsor: A2 Biotherapeutics Inc.

Sex: All·Age: 18+

Code: NCT06682793·Phase 1, Phase 2·Recruiting·Listed Nov 2024

Apply to this trial

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

for Advanced Solid Tumor

Sites in New York +13 more locations

Sponsor: Fate Therapeutics

Sex: All·Age: 18+

Code: NCT06241456·Phase 1·Recruiting·Listed Feb 2024

Apply to this trial

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

for Low-grade Glioma

Sites in New York +11 more locations

Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All·Age: 6 Months - 25

Code: NCT04775485·Phase 2·Recruiting·Listed Mar 2021

Apply to this trial

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

for Advanced Solid Tumor

Sites in New York +12 more locations

Sponsor: Volastra Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05902988·Phase 1, Phase 2·Recruiting·Listed Jun 2023

Apply to this trial

Study of GS-2426 in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

Sites in New York +3 more locations

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT07601243·Phase 1·Recruiting·Listed May 2026

Apply to this trial

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

for Solid Tumors

Sites in New York +5 more locations

Sponsor: Zai Lab (Shanghai) Co., Ltd.

Sex: All·Age: 18+

Code: NCT07374848·Phase 1·Recruiting·Listed Jan 2026

Apply to this trial

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

for Non-small Cell Lung Cancer (NSCLC)

Sites in New York +8 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT07349537·Phase 1·Recruiting·Listed Jan 2026

Apply to this trial

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

for Solid Tumors

Sites in New York +7 more locations

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT07195916·Phase 1·Recruiting·Listed Sep 2025

Apply to this trial

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

for Advanced Solid Tumor

Sites in New York +2 more locations

Sponsor: EMD Serono Research & Development Institute, Inc.

Sex: All·Age: 18+

Code: NCT07166601·Phase 1·Recruiting·Listed Sep 2025

Apply to this trial

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

for Solid Tumor

Sites in New York +7 more locations

Sponsor: Alyssum Therapeutics

Sex: All·Age: 18+

Code: NCT06234098·Phase 1, Phase 2·Recruiting·Listed Jan 2024

Apply to this trial

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

for Advanced Solid Tumors

Sites in New York +8 more locations

Sponsor: Accent Therapeutics

Sex: All·Age: 18+

Code: NCT06799065·Phase 1·Recruiting·Listed Jan 2025

Apply to this trial

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

for Metastatic Hepatocellular Carcinoma

Sites in New York +8 more locations

Sponsor: Tyra Biosciences, Inc

Sex: All·Age: 18+

Code: NCT06915753·Phase 1·Recruiting·Listed Apr 2025

Apply to this trial

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

for Advanced Solid Tumors

Sites in New York +5 more locations

Sponsor: SEED Therapeutics, Inc.

Sex: All·Age: 16+

Code: NCT07197554·Phase 1·Recruiting·Listed Sep 2025

Apply to this trial

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

for Advanced Solid Tumors

Sites in New York +2 more locations

Sponsor: Eikon Therapeutics

Sex: All·Age: 18+

Code: NCT07262619·Phase 1, Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

Sites in New York +4 more locations

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT06167317·Phase 1·Recruiting·Listed Dec 2023

Apply to this trial

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

for Melanoma

Sites in New York +6 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 6 Months - 17

Code: NCT02332668·Phase 1, Phase 2·Recruiting·Listed Jan 2015

Apply to this trial

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

for Solid Tumor

Sites in New York +8 more locations

Sponsor: Sanofi

Sex: All·Age: 18+

Code: NCT05584670·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial